Phaseline

Companies › Lantheus Biosciences

Lantheus Biosciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[18F]PI-2620
Tau PET imaging agent
–Phase 3Alzheimer Disease; Parkinson's DiseaseMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07020026[18F]PI-2620Phase 2Parkinson's DiseaseNeurologyApr 2027
NCT05641688[18F]PI-2620Phase 3Alzheimer DiseaseNeurologyMar 2028

From the company's SEC filings

Cash of $684m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.